Tumour detection startup Cispoly received $14 M Series B funding from Aramco unit

The Middle East has recently become a major source of funding for Asian startups. Among them is Cispoly, a Chinese manufacturer of devices for gynecological tumor detection.

The startup has secured series B funding totaling more than 100 million yuan or USD 14 million. Sunland Fund, an existing investor, joined Prosperity7 Ventures, the diversified growth fund of Saudi energy giant Aramco, in leading the round.

Liu Pei founded Cispoly in 2020. The company produces products for women’s reproductive microbiota testing as well as methylation detection tools for early-stage gynecological tumors, such as cervical, ovarian, and endometrial cancer.

China’s National Medical Products Administration approved Ciscer, Cispoly’s flagship product for real-time cervical cancer detection, in March, the company said. In the works are two new products: Cisova, which is almost ready for clinical testing, and Cisendo, an endometrial cancer screening solution that is presently undergoing clinical trials.

Series B funds will be used by Cispoly for product registration expediting, worldwide expansion, and research and development. The startup has recently begun conducting research in China and intends to work with medical institutions to expand into Southeast Asia and Europe.

Prosperity7 Ventures has previously made investments in Chinese healthtech startups. It has previously supported Fourier Intelligence in its series C and D rounds, which produces exoskeleton robotics products for rehabilitation exercise.

Other investments made by the fund last year included US $28.7 million in China’s Jiandanxinli and US $35 million in Hong Kong’s Insilico Medicine.